Recent Advances in Treatment of Advanced Urothelial Carcinoma

Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05).

(2017) S. Krege et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC).

(2017) M. D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells

(2015) Madhav Sharma et al.   Journal for ImmunoTherapy of Cancer

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

(2009) G. K. Philips et al.   ANNALS OF ONCOLOGY

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

(2009) Daniel P. Petrylak et al.   BJU INTERNATIONAL

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on Cardiac Toxicity With Trastuzumab and Radiotherapy: The Question Is Still Ongoing

(2009) Nicolas Magné et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

(2008) Padmanee Sharma et al.   JOURNAL OF IMMUNOTHERAPY